Monoclonal antibodies against interleukin 6 are being investigated and used in COVID-19. These drugs have been found to reduce mortality in critically ill patients with COVID-19 pneumonia. Tocilizumab is a known immunomodulatory drug commonly used in rheumatoid arthritis. Its purpose in covid had been looked at in this trial.
Remdesivir has a lot of attention as promising antiviral agent against COVID-19. This largest coronavirus study cast a shadow of doubt on effectiveness of remdesivir and other agents on mortality of patients with COVID-19.
In pursue of effective treatment for severe COVID-19 many different antiviral medication have been used. Combined HIV treatment lopinavir-ritonavir showed some inhibitory activity against SARS-CoV-1 and therefore was trialled in new coronavirus causing COVID-19.
While the world awaits an efficient vaccine for coronavirus, many therapeutics are currently being investigated in hope to improve clinical outcomes. One of the most promising one is currently remdesivir. Wang et al. published the first randomised placebo-controlled trial of its use in severe COVID-19.